Hypercalcemia of malignancy: Cancer treatment can be a cause as well.

IF 1.1 4区医学 Q3 UROLOGY & NEPHROLOGY

Clinical nephrology Pub Date : 2024-09-01 DOI:10.5414/CN111403

Hassan Izzedine, Rose Mary Attieh, Farhana Begum, Yee-Ming Melody Cheung, Kenar D Jhaveri

引用次数: 0

Abstract

While the incidence of hypercalcemia of malignancy (HCM) is on the decline, it still occurs in up to 30% of patients with cancer. Immune checkpoint inhibitor (ICI)-related hypercalcemia is becoming increasingly recognized. We describe a case of cemiplimab-induced hypercalcemia in a patient with metastatic squamous cell carcinoma of the earlobe and discuss a management algorithm for HCM. Timely diagnosis and management of HCM is critical for optimal care and the prevention of complications.

查看原文本刊更多论文

恶性肿瘤引起的高钙血症：癌症治疗也可能是原因之一。

虽然恶性肿瘤高钙血症（HCM）的发病率正在下降，但仍有高达 30% 的癌症患者会出现这种情况。与免疫检查点抑制剂（ICI）相关的高钙血症正被越来越多的人所认识。我们描述了一例耳垂转移性鳞状细胞癌患者因塞米单抗诱发的高钙血症，并讨论了HCM的管理算法。及时诊断和处理高钙血症对于优化护理和预防并发症至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nephrology 医学-泌尿学与肾脏学

CiteScore

2.10

自引率

9.10%

发文量

138

审稿时长

4-8 weeks

期刊介绍： Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.